Wedbush reissued their outperform rating on shares of Nps Pharmaceuticals Incorporated (NASDAQ: NPSP) in a report released on Wednesday. Wedbush currently has a $22.00 target price on the stock, up from their previous target price of $19.00.

“NPSP announced the buy-back of ex-US rights from Takeda for Gattex (Revestive in Europe) and Natpara (Preotact in Europe) for 6M newly issued NPSP shares and $30M in cash or shares if combined global sales reach $750M. Recall that Takeda acquired the ex-US rights for these products through its acquisition of Nycomed in 2011. … We view this as a positive transaction for NPSP as Takeda had not put effort into commercialization.,” Wedbush’s analyst wrote.

Nps Pharmaceuticals Incorporated (NASDAQ: NPSP) opened at 9.84 on Wednesday. Nps Pharmaceuticals Incorporated has a 52-week low of $6.32 and a 52-week high of $11.22. The stock’s 50-day moving average is currently $8.42. The company’s market cap is $855.2 million.

NPSP has been the subject of a number of other recent research reports. Analysts at Jefferies Group raised their price target on shares of Nps Pharmaceuticals Incorporated from $15.00 to $16.00 in a research note to investors on Wednesday. They now have a buy rating on the stock. Separately, analysts at Canaccord Genuity raised their price target on shares of Nps Pharmaceuticals Incorporated from $16.00 to $20.00 in a research note to investors on Tuesday. They now have a buy rating on the stock. Finally, analysts at Brean Murray downgraded shares of Nps Pharmaceuticals Incorporated from a buy rating to a hold rating in a research note to investors on Tuesday.

Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $16.33.

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is a biopharmaceutical company focused on the development of new treatment options for patients with gastrointestinal and endocrine disorders and medical needs.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.